The company announced a Class I recall of its AXIOS Stent and Electrocautery-Enhanced Delivery Systems due to serious deployment complications. It also arranged $11 billion in new financing to support its pending acquisition of Penumbra. Recent share price gains over one day and one week contrast with negative returns over the past one and three months. The company received several analyst rating updates following its fiscal Q4 and full-year earnings report.